Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Drak2 Does Not Regulate TGF-β Signaling in T Cells.
Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
American Society for Cell Biology Annual Meeting
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
Motor skill learning requires active central myelination.
Vitamin D intake and incidence of multiple sclerosis.
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
[Intractable vomiting as first manifestation of neuromyelitis Optica.]
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Combination Treatment of Interferon β-1b and Warfarin for a Patient With Baló's Concentric Sclerosis and Antiphospholipid Syndrome.
4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
Microglia activation is associated with IFN-α induced depressive-like behavior.
Epidemiology of Neuromyelitis Optica in the United States: A Multicenter AnalysisEpidemiology of NMO.
Pages
« first
‹ previous
…
126
127
128
129
130
131
132
133
134
…
next ›
last »